Qurient acquires patent of Quinolinyloxyphenylsulfonamides related to cancer treatment
Qurient gave an official notice on the 12th that it acquired a patent of Quinolinyloxyphenylsulfonamides related to cancer treatment.
According to the company, the patent is about the core chemical structure of the anticancer immunity/resistance study and the use of its compound.(patentee: Max P...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
